Search
Patexia Community

Innovation, Technology, and IP News

FDA Approves Qalsody™ for Treatment of ALS

Written by: Douglas W. Crandell, Ph.D. & Robert J. Hilton, Ph.D. On April 25th, 2023, the U.S. Food and Drug Administration (FDA) approved QalsodyTM (tofersen) for the...

Brain Computer Interface Developer Announces $33M Series A, Granted FDA “Breakthrough” Designation

Written by:Tom Cowan Brain computer interface developer Paradromics on May 18, 2023, announced a $33 million Series A funding round as well as a...

If a Case Was Baseless, It Would Have Ended Sooner

Written by: Matthew Pham & Daniel P. Hughes OneSubsea IP UK Limited v. FMC Technologies, Inc. Before Clevenger, Moore, and Dyk.  Appeal from the United States District...

Low-Bar for Corroboration

Written by: Matthew Friedrichs & Daniel P. Hughes MEDTRONIC, INC. v. TELEFLEX INNOVATIONS S.A.R.L. Before Moore, Lourie, and Dyk. Appeal from the Patent Trial and Appeal...

Trademark Monitoring and Enforcement in the Digital Era: Tools and Techniques

In today's digital landscape, protecting your trademarks has become more challenging than ever before. With the rise of e-commerce platforms, social media, and online marketplaces, ...

Feed tagged as "biosimilars":
Most of the community involved in life science litigation and pharmaceutical companies, thought they saw the end of the long-fought battle ... Read More »
In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed... Read More »
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the... Read More »
In late August we released our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape by providing... Read More »
Two days ago, the companies that joined forces in order to develop the first Covid vaccine that got approval for emergency use by FDA... Read More »
Less than two months ago, Curevac filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech over patent... Read More »
AMGEN INC. v. HOSPIRA, INC. Before Moore, Bryson, and Chen.  Appeal from the United States District Court for the District of Delaware. Summary... Read More »
In a recent development with the ongoing complex litigation involving Janssen Biotech’s arthritis biologic medicine Remicade (infliximab) and Celltrion’s... Read More »
Written by Daniel A. Kamkar and Agnes Juang, Ph.D. Janssen Biotech Inc. and Celltrion Healthcare have taken the next step over Janssen’s blockbuster... Read More »
Written by Daniel K. Yarbrough, Ph.D. and Kerry S. Taylor, Ph.D. Bevacizumab (Avastin®) is the subject of the widely watched “patent dance”... Read More »
Written by Robert J. Hilton, Ph.D. and Jing Liu, Ph.D. On January 13, 2017, the Supreme Court granted certiorari in Amgen v. Sandoz, 794. f. 3d 1347 (Fed. Cir... Read More »
Biological pharmaceuticals are therapeutic drugs made from human or animal materials rather than chemicals, often indicated for immune system-related deficiencies... Read More »
The US Food and Drug Administration (FDA) today issued three draft guidance documents on biosimilar product development to assist industry in developing these... Read More »
  For swimmers looking to gain an edge on their competition, the notion that simply donning a high-tech swimsuit -- the surface of which was inspired by... Read More »
Yesterday, Samsung and Biogen announced that they have entered an agreement for the development, manufacturing, and marketing of biosimilars. Samsung Biologics was... Read More »
Menu